The Event Centre is your hub for session recordings and expert highlights from our medical education events over the years, offering a comprehensive archive of learning and insights.
.png?width=1208&height=908&format=png&quality=60)

Prof. Birtle highlights the need for holistic patient assessment and responsive treatment strategies in mHSPC based on consistent trial results, along with unanswered questions around PSA‑driven decisions.

Prof. Timsit discusses how multidisciplinary collaboration, genetic testing, trial interpretation and treatment selection can shape modern management of metastatic prostate cancer.

Prof. von Amsberg highlights the importance of aligning mHSPC treatment choices with individual patient goals, quality of life, and clinical factors.

Prof. Verbeke outlines patient considerations and timing of BRCA testing, and how evolving molecular and digital pathology can improve personalised prostate cancer care.
Watch Prof. Dr. Christian Schwentner, Prof. Dr. Athanasios Papatsoris and Prof. Gert Attard examine how PSA response guides optimal care in mHSPC and share approaches to improve outcomes in HRR-mutant diease.

Prof. Dr. Christian Schwentner discusses new research on mHSPC treatment, the role of biomarkers, and key barriers to better prostate cancer care.
Prof. Dr. Athanasios (Thanos) Papatsoris discusses the need for better patient stratification and evidence-based, optimised treatment for a range of patients with mHSPC.
Prof. Gert Attard explores how early genetic testing and new therapies are transforming prostate cancer care.
Watch the expert panel including Dr. Elena Castro, Prof. Dr. Axel Heidenreich and Dr. Alejo Rodríguez-Vida discuss key considerations in GU care.

Dr. Alejo Rodríguez-Vida explores optimising patient-centred care in mHSPC, including treatment personalisation and insights from recent clinical analyses.
Prof. Dr. Axel Heidenreich highlights the importance of early genomic testing to guide treatment decisions for patients with mHSPC and HRR mutations.
Dr. Elena Castro discusses how genetic testing, treatment personalisation, and biomarker-driven strategies can address unmet needs in mHSPC while balancing rapid clinical advances with practical implementation challenges.
Prof. Dr. Axel Heidenreich addresses the role of molecular testing, emerging trial data, and strategies to advance personalised, patient-centred care across the prostate cancer journey.
Dr. Alejo Rodríguez-Vida examines how emerging data and research can guide personalised treatment, address unmet needs, and shape the future of care for patients with mHSPC.
Watch below as Dr. Miguel Ramírez-Backhaus, Prof. Jozefina Casuscelli and Prof. Gert Attard explore the importance of early detection and screening in metastatic prostate cancer.

The recorded content may not be available in your country. To request access to recordings and session materials, please contact our team.
To report an Adverse Event (medication side-effect) or a Product Quality Complaint (an issue with one of our products), please select the appropriate link from the Contact dropdown menu. To submit a medical information request, choose the Medical Information page.
BRCA, breast cancer gene; GU, genitourinary; HRR, homolgous recombinant repair; mHSPC, metastatic hormone-sensitive prostate cancer; PSA, prostate-specific antigen.













